[HTML][HTML] Bortezomib as the sole post‐renal transplantation desensitization agent does not decrease donor‐specific anti‐HLA antibodies
R Sberro‐Soussan, J Zuber… - American Journal of …, 2010 - Elsevier
Persistence of donor‐specific anti‐HLA antibodies (DSA) associated with antibody‐
mediated graft injuries following kidney transplantation predicts evolution toward chronic
humoral rejection and reduced graft survival. Targeting plasma cells, the main antibody‐
producing cells, with the proteasome inhibitor bortezomib may be a promising
desensitization strategy. We evaluated the in vivo efficacy of one cycle of bortezomib (1.3
mg/m 2× 4 doses), used as the sole desensitization therapy, in four renal transplant …
mediated graft injuries following kidney transplantation predicts evolution toward chronic
humoral rejection and reduced graft survival. Targeting plasma cells, the main antibody‐
producing cells, with the proteasome inhibitor bortezomib may be a promising
desensitization strategy. We evaluated the in vivo efficacy of one cycle of bortezomib (1.3
mg/m 2× 4 doses), used as the sole desensitization therapy, in four renal transplant …